Overview

Lamivudine and Therapeutic Vaccine Evaluation in Senegalese Patients With Chronic Hepatitis B Infection (ANRS 12100 HEPADAK-2)

Status:
Terminated

Trial end date:
2008-07-01

Target enrollment:

Participant gender:

Summary

Chronic hepatitis B infection is a major public health issue in Senegal. The study will compare the efficacy of the treatment strategy combining Lamivudine and therapeutic vaccine (12 intra-muscular injections over a 6-month period) to a treatment with Lamivudine alone on the control of viral replication in patients with a replicative hepatitis B virus (HBV) infection and an increase in hepatic enzymes.

Phase:

Phase 3

Details

Lead Sponsor:

French National Agency for Research on AIDS and Viral Hepatitis

Collaborator:

GlaxoSmithKline

Treatments:

Lamivudine
Vaccines